NME Outlook: Diabetes Drugs May Be Head Of The Class In 2005
The coming year could bring three significant approvals for novel classes of diabetes drugs: Amylin's Symlin, Lilly/Amylin's exenatide and Bristol-Myers Squibb/Merck's muraglitazar
The coming year could bring three significant approvals for novel classes of diabetes drugs: Amylin's Symlin, Lilly/Amylin's exenatide and Bristol-Myers Squibb/Merck's muraglitazar